Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.95
+0.19 (1.01%)
Oct 29, 2026, 10:33 AM EDT - Market open
Immunome Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 6.94 | 9.04 | 14.02 | - | - | |
Revenue Growth | - | -23.23% | -35.50% | - | - | - |
Cost of Revenue | 206.23 | 177.29 | 129.54 | 23.09 | 23.11 | - |
Gross Profit | -206.23 | -170.35 | -120.5 | -9.07 | -23.11 | - |
Selling, General & Admin | 54.24 | 43.77 | 32.96 | 19.66 | 13.79 | 11.09 |
Research & Development | - | - | - | - | - | 14.11 |
Operating Expenses | 54.24 | 43.77 | 32.96 | 19.66 | 13.79 | 25.2 |
Operating Income | -260.47 | -214.11 | -153.46 | -28.73 | -36.9 | -25.2 |
Interest Expense | - | - | - | - | - | -0.01 |
Interest & Investment Income | 16.14 | 11.72 | 12.84 | 2.72 | 0.01 | - |
EBT Excluding Unusual Items | -244.32 | -202.39 | -140.62 | -26 | -36.9 | -25.21 |
Other Unusual Items | - | - | - | - | - | 0.5 |
Pretax Income | -254.32 | -212.39 | -292.96 | -106.81 | -36.9 | -24.71 |
Net Income | -254.32 | -212.39 | -292.96 | -106.81 | -36.9 | -24.71 |
Preferred Dividends & Other Adjustments | - | - | - | - | 0.62 | - |
Net Income to Common | -254.32 | -212.39 | -292.96 | -106.81 | -37.52 | -24.71 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 102 | 87 | 59 | 20 | 12 | 12 |
Shares Outstanding (Diluted) | 102 | 87 | 59 | 20 | 12 | 12 |
Shares Change | 41.38% | 48.96% | 195.51% | 63.64% | 5.10% | 240.41% |
EPS (Basic) | -2.49 | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 |
EPS (Diluted) | -2.49 | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -219.09 | -200.6 | -117.97 | -8.4 | -28.94 | -18.31 |
Free Cash Flow Per Share | -2.14 | -2.30 | -2.01 | -0.42 | -2.39 | -1.59 |
Gross Margin | - | - | - | -64.71% | - | - |
Operating Margin | - | -3084.76% | -1697.33% | -204.94% | - | - |
Profit Margin | - | -3059.99% | -3240.38% | -761.92% | - | - |
Free Cash Flow Margin | - | -2890.13% | -1304.80% | -59.92% | - | - |
EBITDA | -257.69 | -211.65 | -151.89 | -28.27 | -36.48 | -24.45 |
EBITDA Margin | - | - | - | -201.68% | - | - |
D&A For EBITDA | 2.78 | 2.47 | 1.57 | 0.46 | 0.42 | 0.76 |
EBIT | -260.47 | -214.11 | -153.46 | -28.73 | -36.9 | -25.2 |
EBIT Margin | - | - | - | -204.94% | - | - |